2022: The Year of Psilocybin | Numinus Wellness $NUMI $NUMIF

Numinus Wellness Inc (TSE: NUMI, OTCMKTS: NUMIF) is a Canadian company that helps cure people’s mental health through psychedelic-assisted therapies. The Numinus Wellness model – including psychedelic production, research and clinical care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance abuse.

Numinus has three business divisions – a Health Canada-licensed lab developing IP while offering analytics services for revenue generation, an R&D division developing psychedelic-assisted therapeutic protocols to embed in mainstream healthcare, and a health practitioner division delivering treatments in Numinus-owned clinics.

“Numinus Health, which is our clinical infrastructure doing traditional mental health services as well as ketamine assisted psychotherapy and now looking to 2022 is really next year being about implementing and integrating MDMA and psilocybin assisted therapy. Which MDMA is expected to be legal for therapy in 2023. So, it’s really getting the foundation in place to be ready for that.” – Numinus Wellness CEO Payton Nyquvest

Numinus was the first Canadian public company to complete a legal harvest of psilocybin (magic mushrooms). But 2022 could be the year that psilocybin finally comes to market. There are numerous section 56 exemptions within the Controlled Drugs and Substances Act that Health Canada has granted for psilocybin use. These exemptions may suggest that broader medical use of psilocybin may be on the horizon. Numinus is looking to take advantage and has psilocybin extract products when they can.

“You’re seeing a really interesting regulatory environment in Canadain in particular at the moment around psilocybin which may allow for us to start to have psilocybin-based products in markets next year as well. You’re seeing a couple of interesting catalysts around the psychotherapy side of things and starting to be able to find a market for the drug itself outside of research.” – Numinus Wellness CEO Payton Nyquvest

Watch the full CEO interview to learn about Numinus’s uplisting to the TSX, future senior US listings, acquisitions like the Neurology Centre of Toronto, and the company using psilocybin to cure mental health problems.

Original article: 2022: The Year of Psilocybin | Numinus Wellness $NUMI $NUMIF

©2021 Midas Letter. All Rights Reserved.